George Kalema, PhD

Dr
Keyrus Biopharma, Waterloo, Belgium, on behalf of GSK

Disclosure: GSK group of companies/Keyrus Biopharma (Individual(s) Involved: Self): Consultant

Presentation(s):

• 8 - The Adjuvanted Recombinant Zoster Vaccine (RZV) Confers Long-term Protection Against Herpes Zoster: Interim Results of an Extension Study (ZOSTER-049) of Two Clinical Trials (ZOE-50 and ZOE-70)

  Oral Abstract